Protective Effects of Monoclonal Antibodies against Parainfluenza Virus Type 3-induced Brain Infection in Hamsters

Production of monoclonal antibodies against parainfluenza 3 virus and their use in diagnosis by immunofluorescence.

Monoclonal antibodies were produced against parainfluenza virus type 3 (PI-3) and used to identify PI-3 clinical isolates in cell culture and PI-3 antigen in cells obtained from nasopharyngeal (NP) washes of patients. Two (2E9 and 4G5) of the three monoclonal antibodies characterized reacted by immunoblotting with a 67,000-dalton PI-3 protein, and one antibody (4E5) reacted with two viral prote...

Kawasaki disease associated with parainfluenza type 3 virus infection.

Kawasaki disease (KD) is an acute, febrile and multisystem vasculitis of early childhood with a striking predilection for the coronary arteries. In developed countries, the incidence of KD has replaced acute rheumatic fever as the leading cause of acquired heart disease in children. The etiologic agent of KD remains unknown, although clinical and epidemiologic features strongly indicate an infe...

Serological survey for antibodies against infectious bovine rhinotracheitis and parainfluenza 3 viruses among cattle in Iran

Monoclonal antibodies against human paramyxovirus type 3 and against SV5 virus: preparation and preliminary characterization.

Monoclonal antibodies against the major glycoprotein (HN) and the nucleoprotein (NP) of paramyxovirus SV5 and human paramyxovirus (PF) type 3 have been obtained. Two different epitopes have been detected on the SV5 HN polypeptide, one being specific to SV5 and the other also cross-reacting with PF-2 HN polypeptide. Monoclonal antibody against SV5 NP polypeptide also reacted with PF-2 NP polypep...

Potent neutralizing monoclonal antibodies against Ebola virus infection.

Ebola virus infections cause a deadly hemorrhagic disease for which no vaccines or therapeutics has received regulatory approval. Here we show isolation of three (Q206, Q314 and Q411) neutralizing monoclonal antibodies (mAbs) against the surface glycoprotein (GP) of Ebola virus identified in West Africa in 2014 through sequential immunization of Chinese rhesus macaques and antigen-specific sing...